Healthcare provider profile · identity verified

John Ray Groeneveld, MD

Family Practice · IRON MOUNTAIN, MI · NPI 1467452391

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	788	177
Omeprazole	Omeprazole	576	123
Lisinopril	Lisinopril	569	138
Amlodipine Besylate	Amlodipine Besylate	526	121
Simvastatin	Simvastatin	504	118
Levothyroxine Sodium	Levothyroxine Sodium	444	90
Losartan Potassium	Losartan Potassium	405	84
Rosuvastatin Calcium	Rosuvastatin Calcium	388	108
Metoprolol Succinate	Metoprolol Succinate	356	75
Pravastatin Sodium	Pravastatin Sodium	350	79
Metformin Hcl	Metformin Hcl	332	73
Fluticasone Propionate	Fluticasone Propionate	312	105
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	284	72
Eliquis	Apixaban	236	50
Gabapentin	Gabapentin	232	50
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	226	56
Metformin Hcl Er	Metformin Hcl	209	51
Tamsulosin Hcl	Tamsulosin Hcl	200	55
Escitalopram Oxalate	Escitalopram Oxalate	192	46
Metoprolol Tartrate	Metoprolol Tartrate	181	40
Hydrochlorothiazide	Hydrochlorothiazide	174	41
Allopurinol	Allopurinol	171	37
Jardiance	Empagliflozin	168	35
Furosemide	Furosemide	161	36
Trazodone Hcl	Trazodone Hcl	148	34
Pantoprazole Sodium	Pantoprazole Sodium	139	34
Carvedilol	Carvedilol	138	30
Ezetimibe	Ezetimibe	135	34
Alendronate Sodium	Alendronate Sodium	130	35
Duloxetine Hcl	Duloxetine Hcl	119	27
Albuterol Sulfate Hfa	Albuterol Sulfate	117	35
Clopidogrel	Clopidogrel Bisulfate	114	24
Donepezil Hcl	Donepezil Hcl	114	24
Famotidine	Famotidine	112	22
Montelukast Sodium	Montelukast Sodium	107	23
Arexvy	Rsvpref3 Antigen/As01e/Pf	102	102
Finasteride	Finasteride	100	29
Potassium Chloride	Potassium Chloride	89	21
Sertraline Hcl	Sertraline Hcl	89	23
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	85	13
Triamcinolone Acetonide	Triamcinolone Acetonide	80	39
Trulicity	Dulaglutide	78	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	72	24
Warfarin Sodium	Warfarin Sodium	72	15
Aripiprazole	Aripiprazole	70	14
Buspirone Hcl	Buspirone Hcl	69	15
Paroxetine Hcl	Paroxetine Hcl	68	13
Amitriptyline Hcl	Amitriptyline Hcl	61	14
Citalopram Hbr	Citalopram Hydrobromide	58	12
Memantine Hcl	Memantine Hcl	58	suppressed
Ozempic	Semaglutide	53	12
Spironolactone	Spironolactone	52	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	51	13
Mounjaro	Tirzepatide	50	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	48	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	46	suppressed
Xarelto	Rivaroxaban	43	11
Symbicort	Budesonide/Formoterol Fumarate	42	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	40	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	38	suppressed
Prednisone	Prednisone	38	12
Atenolol	Atenolol	36	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Lamotrigine	Lamotrigine	36	suppressed
Ramipril	Ramipril	35	suppressed
Synthroid	Levothyroxine Sodium	35	suppressed
Bupropion Xl	Bupropion Hcl	34	suppressed
Humalog Kwikpen U-100	Insulin Lispro	32	suppressed
Breo Ellipta	Fluticasone/Vilanterol	30	suppressed
Ipratropium Bromide	Ipratropium Bromide	29	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	29	suppressed
Celecoxib	Celecoxib	28	suppressed
Glimepiride	Glimepiride	28	suppressed
Lovastatin	Lovastatin	28	suppressed
Pregabalin	Pregabalin	27	suppressed
Tradjenta	Linagliptin	27	suppressed
Dutasteride	Dutasteride	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Amiodarone Hcl	Amiodarone Hcl	24	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	24	suppressed
Bumetanide	Bumetanide	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Clobetasol Propionate	Clobetasol Propionate	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	18
Insulin Aspart Flexpen	Insulin Aspart	23	suppressed
Azithromycin	Azithromycin	22	11
Enalapril Maleate	Enalapril Maleate	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Invokana	Canagliflozin	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Valsartan	Valsartan	19	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Ketoconazole	Ketoconazole	16	14
Nystatin	Nystatin	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Jentadueto	Linagliptin/Metformin Hcl	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	15	suppressed
Budesonide Dr	Budesonide	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Cephalexin	Cephalexin	13	suppressed
Estradiol	Estradiol	13	suppressed
Glyxambi	Empagliflozin/Linagliptin	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Enbrel Sureclick	Etanercept	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Digoxin	Digoxin	11	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	11	suppressed
Methenamine Hippurate	Methenamine Hippurate	11	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed
Serevent Diskus	Salmeterol Xinafoate	11	suppressed
Tadalafil	Tadalafil	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error